SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution.

Mirzaa, G; Timms, AE; Conti, V; Boyle, EA; Girisha, KM; Martin, B; Kircher, M; Olds, C; Juusola, J; Collins, S; et al. Mirzaa, G; Timms, AE; Conti, V; Boyle, EA; Girisha, KM; Martin, B; Kircher, M; Olds, C; Juusola, J; Collins, S; Park, K; Carter, M; Glass, I; Krägeloh-Mann, I; Chitayat, D; Parikh, AS; Bradshaw, R; Torti, E; Braddock, S; Burke, L; Ghedia, S; Stephan, M; Stewart, F; Prasad, C; Napier, M; Saitta, S; Straussberg, R; Gabbett, M; O'Connor, BC; Keegan, CE; Yin, LJ; Lai, AHM; Martin, N; McKinnon, M; Addor, M-C; Boccuto, L; Schwartz, CE; Lanoel, A; Conway, RL; Devriendt, K; Tatton-Brown, K; Pierpont, ME; Painter, M; Worgan, L; Reggin, J; Hennekam, R; Tsuchiya, K; Pritchard, CC; Aracena, M; Gripp, KW; Cordisco, M; Van Esch, H; Garavelli, L; Curry, C; Goriely, A; Kayserilli, H; Shendure, J; Graham, J; Guerrini, R; Dobyns, WB (2016) PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution. JCI Insight, 1 (9). e87623. ISSN 2379-3708 https://doi.org/10.1172/jci.insight.87623
SGUL Authors: Tatton-Brown, Katrina Louise

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (842kB) | Preview

Abstract

Mosaicism is increasingly recognized as a cause of developmental disorders with the advent of next-generation sequencing (NGS). Mosaic mutations of PIK3CA have been associated with the widest spectrum of phenotypes associated with overgrowth and vascular malformations. We performed targeted NGS using 2 independent deep-coverage methods that utilize molecular inversion probes and amplicon sequencing in a cohort of 241 samples from 181 individuals with brain and/or body overgrowth. We identified PIK3CA mutations in 60 individuals. Several other individuals (n = 12) were identified separately to have mutations in PIK3CA by clinical targeted-panel testing (n = 6), whole-exome sequencing (n = 5), or Sanger sequencing (n = 1). Based on the clinical and molecular features, this cohort segregated into three distinct groups: (a) severe focal overgrowth due to low-level but highly activating (hotspot) mutations, (b) predominantly brain overgrowth and less severe somatic overgrowth due to less-activating mutations, and (c) intermediate phenotypes (capillary malformations with overgrowth) with intermediately activating mutations. Sixteen of 29 PIK3CA mutations were novel. We also identified constitutional PIK3CA mutations in 10 patients. Our molecular data, combined with review of the literature, show that PIK3CA-related overgrowth disorders comprise a discontinuous spectrum of disorders that correlate with the severity and distribution of mutations.

Item Type: Article
Additional Information: Copyright © 2016 Mirzaa et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Keywords: Class I Phosphatidylinositol 3-Kinases, Female, Genetic Association Studies, High-Throughput Nucleotide Sequencing, Humans, Infant, Male, Malformations of Cortical Development, Mosaicism, Mutation, Phenotype, Tissue Distribution, Vascular Malformations, Humans, Tissue Distribution, Phenotype, Mutation, Mosaicism, Infant, Female, Male, Vascular Malformations, Malformations of Cortical Development, Genetic Association Studies, Class I Phosphatidylinositol 3-Kinases, High-Throughput Nucleotide Sequencing
SGUL Research Institute / Research Centre: Academic Structure > Institute of Medical & Biomedical Education (IMBE)
Journal or Publication Title: JCI Insight
ISSN: 2379-3708
Language: eng
Dates:
DateEvent
16 June 2016Published
17 May 2016Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
U54 HD083091NICHD NIH HHSUNSPECIFIED
R01 NS092772NINDS NIH HHSUNSPECIFIED
R01 HL130996NHLBI NIH HHSUNSPECIFIED
K08 NS092898NINDS NIH HHSUNSPECIFIED
102731Wellcome Trusthttp://dx.doi.org/10.13039/100004440
N602531Seventh Framework Programmehttp://dx.doi.org/10.13039/501100004963
PubMed ID: 27631024
Web of Science ID: WOS:000387112700014
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/111377
Publisher's version: https://doi.org/10.1172/jci.insight.87623

Actions (login required)

Edit Item Edit Item